Efficacy, Safety And Tolerability Study In Subjects With Parkinson's Disease

Completed · Phase 1 · Has a placebo group

Conditions studied: Parkinson's Disease

In brief

The B7441003 study will assess PF-06412562 for motor benefit in Parkinson's disease subjects. Safety, tolerability and PK of PF-06412562 in Parkinson's disease subjects will also be evaluated.

Key facts

Study ID

NCT02006290

Run by

Pfizer

People needed

19

Starts

2014-03-01

Expected to finish

2014-08-01

Last updated by the study team

2015-10-02

Who can join

Age: 30 and older, up to 75. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Male or female subjects with a diagnosis of idiopathic Parkinson's disease.
• Daily L-dopa dose between 300 and 1200 mg.
• MBRS score >1.

You may not qualify if…

• Surgical intervention for Parkinson's disease.
• History of troublesome dyskinesias.
• Any significant AXIS I psychiatric disease.

Where it is running

• Pfizer Investigational Site — Aventura, Florida, United States
• Pfizer Investigational Site — Baco Raton, Florida, United States
• Pfizer Investigational Site — South Miami, Florida, United States
• Pfizer Investigational Site — Bingham Farms, Michigan, United States
• Pfizer Investigational Site — Raleigh, North Carolina, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.